P results should be getting closer....interesting to think that the rating scale they are using is more favorable (PASI vs IGA) than the Phase IIa, the patient population will not include mild psoriasis patients this time and they have increased the dose to 300/400 mg. Seems to me they could have stayed at 200 mg and likely shown improvement over the Phase IIa. It will be interesting to see how well P does this time around based upon the above.